The difference between pemetinib/dabotan and first, second and third generation targeted drugs

In the history of targeted drug development, pemigatinib represents a new generation of FGFR-targeted drugs. Compared with traditional first- and second-generation targeted drugs, it has significant advantages in selectivity, targeting accuracy and indication expansion. First-generation targeted drugs are usually characterized by broad-spectrum kinase inhibition. Although effective in some cancers, they have severe side effects and are prone to drug resistance. Second-generation targeted drugs have improved selectivity, but still have non-specific toxicity caused by cross-kinase inhibition. As a new generation of targeted drugs, pemetinib not only improves the efficacy but also significantly reduces the risk of non-target side effects by highly selectively inhibiting FGFR1, FGFR2 and FGFR3.

Compared with earlier targeted drugs, the precision of pemetinib allows for personalized treatment in patients with positive genetic tests. This strategy not only improves the disease control rate, but also prolongs progression-free survival. Early drugs often relied on broad-spectrum inhibition, with a large patient population, but uneven efficacy; pemetinib makes treatment more targeted by accurately identifying patients with FGFR fusions or mutations.

In addition, the new generation of targeted drugs also shows flexibility in delivery modes. The oral small molecule properties of pemetinib make it suitable for long-term management and combination therapy, while early drugs mostly relied on intravenous infusion or had complex dosage intervals, resulting in low patient compliance. Pemetinib has advantages in long-term safety, tolerability and maintenance of quality of life, which is also an important manifestation of its differentiation from first- and second-generation drugs.

Overall, pemetinib is not only ahead of traditional drugs in terms of target selectivity, but also embodies the concept of precision medicine in clinical application, providing a new option for patients with FGFR-positive cholangiocarcinoma (CCA) and some hematological tumors. Its advantages include efficient targeting, long-term management and good safety. This is also the core value of the new generation of targeted drugs in the field of cancer treatment.

Reference materials:https://go.drugbank.com/drugs/DB15102